To improve competitive advantage and capital efficiency, our IPPH Accelerator provides a new pathway to integrate excellent industry and academic resources that will innovate biomedical discovery, its clinical development, and translation into treatments for people worldwide.

By optimizing complementary capabilities, our collaboration will help you quickly scale and get the answers you need to make decisions by leveraging the University of Chicago and our partners’ tremendous resources, including:

Excellent laboratories / experimental systems
Artificial Intelligence
Deep scientific / clinical acumen
Fresh tissue sourcing
Clinical development expertise

Excellent laboratories / experimental systems
Artificial Intelligence
Deep scientific / clinical acumen
Fresh tissue sourcing
Clinical development expertise

Furthermore, our scientific teams are able to perform the studies for you, which saves you time by eliminating the need to relocate your staff and develop lab space, etc.

To explore opportunities across study design through co-development, please contact Gary Hamill, Ed.D., P.D., Executive Administrator, at ghamill@uchicagomedicine.org

LEARN ABOUT OUR CORPORATE PARTNERS

Johnson & Johnson

Janssen, a Pharmaceutical Company of Johnson & Johnson, focuses their research and development work on six high needs areas of medicine where they can make the biggest difference including infectious disease and vaccines. They have worked to protect people, especially the most vulnerable, from the world’s most challenging and wide-reaching infectious disease including HIV, Ebola, and tuberculosis.

As part of their efforts in combating COVID-19, Janssen partnered with IPPH as a site for the ENSEMBLE Phase 3 clinical trials to evaluate the safety and efficacy of their investigational COVID-19 vaccine using the company’s AdVac® technology. The ENSEMBLE studies enrolled over 70,000 participants in single and two-dose protocols in the United States, South Africa, and six other countries with a focus on efficacy in populations at high-risk of developing complications from COVID-19. IPPH contributed to the success of these trials by enrolling a large number of participants representing a diverse cross-section of the residents of Illinois and Indiana. The ENSEMBLE studies resulted in a highly efficacious tool for combating the COVID-19 pandemic in the United States and internationally.

Freenome

Freenome, a privately-held biotech company based in South San Francisco, and the University of Chicago share a deep commitment to health equity and a belief in meeting patients where they are to ensure everyone has access to innovative research.
Freenome partnered with the IPPH Accelerator for two clinical studies using the company’s innovative multiomics platform. The platform combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages using a standard blood draw.

• The PREEMPT CRC study enrolled more than 40,000 individuals from diverse backgrounds across the United States with the aim of developing a blood test to detect colorectal cancer. It is the largest prospective study of its kind for a blood-based colorectal screening among average-risk adults.
• The Vallania study is enrolling individuals at more than 100 sites as part Freenome’s development of screening tests for additional cancers.